, consisting of: multidomain antiapoptotic BCL-2, BCL-X L and MCL-1; multidomain pro-apoptotic BAX and BAK; and pro-apoptotic BH3-only molecules (BH3s). Multidomain members contain all four BCL-2 homology domains (BH1-4) whereas BH3s share sequence homology only within the BH3 domain. Multiple apoptotic stimuli culminate in mitochondrial outer membrane permeabilization (MOMP), resulting in the release of cytochrome c into the cytosol to activate caspases 4, 5 . The decision of a given cell to undergo MOMP is determined by the interplays among these three BCL-2 subfamilies [1] [2] [3] 6, 7 . BAX and BAK are the essential effectors responsible for MOMP whereas BCL-2, BCL-X L and MCL-1 preserve mitochondrial integrity 8, 9 . BH3s are death sentinels that relay upstream apoptotic signals to initiate apoptosis by either activating BAX-BAK directly ('activator' BH3s) or inactivating BCL-2, BCL-X L and MCL-1 ('inactivator' or 'sensitizer' BH3s; refs 6,9-15) . BH3s execute their function through binding of their BH3 domains into the hydrophobic binding groove of multidomain pro-apoptotic or anti-apoptotic members [16] [17] [18] [19] [20] [21] [22] . BID, BIM and PUMA are 'activator BH3s' that directly interact with BAX-BAK to induce the stepwise structural reorganization and oligomerization of BAX-BAK (refs 6,8,9,14,15) . One important intermediate step of BAX-BAK activation driven by activator BH3s is to expose the BH3 domain of BAX-BAK such that the 'BH3-exposed' BAX-BAK monomer can bind to the hydrophobic dimerization pocket of another BAX-BAK molecule, initiating homo-dimerization and subsequent homo-oligomerization 23, 24 Two non-mutually exclusive models have been proposed concerning how BH3s activate BAX-BAK (refs 2,3) . The direct activation model states that the 'activator' subgroup of BH3s can directly induce the conformational changes of BAX-BAK (refs 6,8,9,14,25,26) . The indirect model proposes that BAX and BAK are kept in check by the anti-apoptotic BCL-2 proteins and activation of BAX-BAK occurs by default as long as all of the antiapoptotic BCL-2s are neutralized by BH3s (ref. 27) . The generation of Bid −/− Bim −/− Puma −/− triple knockout (TKO) mice provides in vivo evidence supporting the direct activation model 15 . However, the observation that double deficiency of Bax and Bak incurs more severe embryonic lethality than triple deficiency of Bid, Bim and Puma (refs 15,28) suggests that either additional activators of BAX-BAK exist in other cell types, or BAX-BAK can be activated through an alternative mechanism that is entirely independent of BH3s. Alternatively, non-apoptotic functions of BAX-BAK, such as regulation of mitochondrial fission/fusion or endoplasmic reticulum (ER) calcium homeostasis 29, 30 , may account for the more severe embryonic lethality of Bax −/− Bak −/− mice. Here, we demonstrate that NOXA is a bona fide activator of BAX and BAK that directly interacts with BAX-BAK to drive the homo-oligomerization of BAX-BAK even in the absence of BID, BIM and PUMA. Owing to the unique high expression of NOXA in mouse embryonic fibroblasts (MEFs), Bid −/− Bim −/− Puma −/− MEFs succumbed to diverse intrinsic apoptotic signals whereas Bid −/− Bim −/− Puma −/− Noxa −/− MEFs were completely resistant to growth factor deprivation or ER stress. Surprisingly, BAX and BAK could be 'autoactivated' by DNA damage in transformed Bid −/− Bim −/− Puma −/− Noxa −/− MEFs through downregulation of BCL-2, BCL-X L and MCL-1. Liberation of a small fraction of 'BH3-exposed' BAK/BAX monomers from the anti-apoptotic BCL2s is sufficient to induce a 'feed-forward' amplification loop for the initiation of mitochondrial apoptosis. Interestingly, BCL-X L is superior to BCL-2 and MCL-1 in preventing DNA damage-induced apoptosis owing to its dual inhibition of BAX and BAK as well as higher protein stability. On the basis of these results, we propose an interconnected hierarchical model that accommodates and explains how the intricate interplays between BH3s, multidomain antiapoptotic and multidomain pro-apoptotic BCL-2 members dictate the cellular decision of survival versus death.
RESULTS
NOXA directly activates BAX and BAK independently of BID, BIM and PUMA Genetic loss-of-function studies indicate that BID, BIM and PUMA are required for the activation of BAX and BAK in neurons and T cells 15 . However, it remains unclear whether BID, BIM and PUMA represent the full repertoire of activator BH3s in all cell types, and whether BAX and BAK can be activated to induce apoptosis in the absence of activator BH3s. To address these questions, we first examined fibroblasts generated from Bid −/− Bim −/− Puma −/− TKO mouse embryos. Although TKO MEFs were significantly more resistant to apoptosis than wild-type MEFs, they eventually succumbed to various apoptotic stimuli ( Supplementary Fig. 1 ). These data suggest the existence of yet unidentified activator(s) of BAX and BAK in fibroblasts. During the process of searching for additional activator(s) of BAX-BAK, we found that recombinant NOXA protein generated using wheat germ extract (WGE) but not reticulocyte lysates was capable of inducing cytochrome c release from mitochondria isolated from wild-type but not Bax −/− Bak −/− cells in a dosedependent manner (Fig. 1a,b) . The cytochrome c-releasing activity of NOXA was abrogated by BH3 mutations (Fig. 1a) , supporting the importance of the BH3 domain in activating BAX-BAK. We have previously demonstrated that in vitro-transcribed, -translated (IVTT) mouse NOXA protein using reticulocyte lysates failed to induce cytochrome c efflux from mitochondria 6 . As we encountered difficulty in generating IVTT human NOXA protein generated using reticulocyte lysates, we exploited WGE. Both human and mouse NOXA generated using WGE exhibited comparable cytochrome c-releasing activity (Fig. 1c) . Notably, the BAD protein could not induce cytochrome c release irrespective of the IVTT system employed (Fig. 1c) . These data suggest that either WGE activates or reticulocyte lysates inhibit the cytochrome c-releasing activity of NOXA. The NOXA protein generated using reticulocyte lysates could not induce cytochrome c release even in the presence of WGE ( Supplementary Fig. 2a ). In contrast, the cytochrome c-releasing activity of the NOXA protein generated using WGE was abrogated by reticulocyte lysates ( Supplementary Fig. 2a ), supporting the theory that an inhibitory factor or activity is present in reticulocyte lysates. Interestingly, the inhibitory effect of reticulocyte lysates seems to be specific for NOXA ( Supplementary Fig. 2a,b) .
We next examined whether NOXA can interact and activate BAX-BAK directly. Indeed, direct interaction between NOXA and BAX or BAK was detected by GST-pulldown assays (Fig. 1d) . Furthermore, wild-type NOXA but not BH3 mutant NOXA induced the formation of BAX or BAK homo-oligomers (Fig. 1e) . More importantly, NOXA induced cytochrome c efflux in (Fig. 1f) . Overexpression of mouse NOXA protein did not induce robust apoptosis possibly owing to its labile nature. Supporting this notion, overexpression of mutant NOXA with substitutions of arginine for all lysine residues that stabilized the NOXA protein significantly enhanced the deathinducing activity of mouse NOXA (Fig. 1g) . Interestingly, human NOXA protein was more stable than mouse NOXA protein and consequently induced more apoptosis (Fig. 1g) . To further validate that NOXA is a bona fide activator BH3, liposome permeabilization assays were performed (Fig. 1h,i) . As previously reported 31, 32 , recombinant BAX protein was unable to induce liposomal release of fluorophore unless it was activated by tBID (Fig. 1h) . By analogy, wildtype NOXA but not BH3 mutant NOXA could induce BAX-dependent liposome permeabilization (Fig. 1h,i) . In contrast, BAD failed to activate BAX to permeabilize liposomes (Fig. 1j,k) . These data strongly support that NOXA can directly activate BAX to induce MOMP.
Noxa deficiency further protects Bid −/− Bim −/− Puma −/− MEFs and small intestine from apoptosis
We reasoned that differential expressions of NOXA in various cell types might contribute to the different apoptotic phenotypes of Bid −/− Bim −/− Puma −/− neurons, T cells and MEFs. Quantitative PCR with reverse transcription (qRT-PCR) demonstrated that NOXA was highly expressed in MEFs compared with neurons and lymphocytes (Fig. 2a) , which is consistent with previous The expression of the indicated proteins was detected by an anti-HA immunoblot. (h,i) ANTS/DPX (fluorophore/quencher)-encapsulated liposomes were incubated with recombinant BAX protein plus the indicated IVTT proteins generated using WGE. The release of entrapped fluorophore monitored with time is shown in h (mean ± s.d., n = 3 independent experiments). The release of entrapped fluorophore at 60 min is shown in i (mean ± s.d., n = 3 independent experiments). (j,k) ANTS/DPX-encapsulated liposomes were incubated with recombinant BAX protein plus the indicated IVTT proteins (WGE). The release of entrapped fluorophore monitored with time is shown in j (mean ± s.d., n = 3 independent experiments). The release of entrapped fluorophore at 60 min is shown in k (mean ± s.d., n = 3 independent experiments). * * , P < 0.01; * * * , P < 0.001 (Student's t-test).
Unprocessed original scans of blots are shown in Supplementary Fig. 7 .
observations that deficiency of Noxa protects transformed MEFs but not lymphocytes from DNA damage-induced apoptosis [33] [34] [35] . Fig. 2b) . Remarkably, the protection conferred by quadruple deficiency of Bid, Bim, Puma and Noxa was comparable to that of double deficiency of Bax and Bak (Fig. 2b) . The reason why deletion of Noxa further protects Bid −/− Bim −/− Puma −/− MEFs is not due to compensatory induction of Noxa (Supplementary Fig. 2c ). Together, these data indicate that NOXA, along with BID, BIM and PUMA, is an activator of BAX-BAK in MEFs. As intermediate expression of NOXA was detected in small intestine (Fig. 2a) where deficiency of Noxa was reported to confer protection against ionizing radiation 34 , we next examined whether deficiency of Noxa further protects
mice were born at a less-than-expected Mendelian ratio and exhibited the same developmental defects including persistent interdigital webs and imperforate vagina ( Supplementary Fig. 2d ,e and Supplementary Table 1 ). Although triple deletion of Bid, Bim and Puma provided profound inhibition of irradiation-induced apoptosis in small intestine, only quadruple deletion of Bid, Bim, Puma and Noxa or double deletion of Bax and Bak completely blocked apoptosis (Fig. 2c,d ). Consistent with the lower NOXA expression in lymphocytes (Fig. 2a) (Fig. 2e) . Of note, Noxa expression is lower both at the basal level and in response to genotoxic stress in T cells than MEFs ( Supplementary Fig. 2f ). Total body irradiation-induced apoptosis in spleen was greatly reduced in both Supplementary Fig. 3a ). Triple deletion of Bid, Bim and Puma or quadruple deletion of Bid, Bim, Puma and Noxa almost completely rescued splenic CD4 + T-cells from irradiation ( Supplementary Fig. 3b ). Collectively, these data suggest that although NOXA can directly activate BAX and BAK, Noxa deficiency confers resistance to apoptosis only in tissues or cell types that express sufficient NOXA for the activation of BAX-and BAK-dependent death program. (Fig. 3a-e) . Consistent with the notion that transformed cells are more dependent on glutamine for survival, transformation of primary MEFs with E1A/Ras sensitizes these cells to glutamine deprivation-induced apoptosis (Fig. 3c) . Deletion of Bid, Bim and Puma greatly reduced whereas deletion of Bid, Bim, Puma and Noxa completely blocked glutamine deprivation-induced apoptosis in E1A/Ras-transformed MEFs (Fig. 3c) . Surprisingly, quadruple deficiency of Bid, Bim, Puma and Noxa failed to provide similar protection against etoposide or ultraviolet as double deficiency of Bax and Bak (Fig. 3f,g ). To exclude the possibility that regulation of BAX-BAK activation is unique in E1A/Ras-transformed cells, primary MEFs were transformed with SV40. Again, SV40-transformed Bid −/− Bim −/− Puma −/− Noxa −/− MEFs were sensitive to etoposide and ultraviolet whereas they were as resistant as SV40-transformed Bax −/− Bak −/− MEFs to ER stress (Fig. 3h) . Together, these data suggest that either an additional activator of BAX-BAK is induced or an alternative mechanism is involved in DNA damageinduced activation of BAX-BAK in transformed MEFs.
Transformed
DNA damage activates BAX-and BAK-dependent mitochondrial apoptosis in transformed
MEFs, we first examined cytochrome c-initiated caspase activation. In SV40-transformed wild-type MEFs, etoposide induced cytochrome c efflux from the mitochondria to the cytosol within 15 h (Fig. 4a ), which coincides with the peak of caspase activation (Fig. 4b) . In contrast, cytochrome c translocation was not detected in
cells until 24 h and was to a much lesser extent than wild-type cells (Fig. 4a) . Accordingly, lower caspase activity was detected in Bid −/− Bim −/− Puma −/− Noxa −/− cells than wild-type cells (Fig. 4b) . Cleavage of PARP and caspase-3 was detected in QKO cells on etoposide but not ER stress (Fig. 4c) . In support of the involvement of the cytochrome c-APAF-1-caspase-9 axis in DNA damage-induced apoptosis in QKO cells, knockdown of cytochrome c, Apaf-1 or caspase-9 protected QKO cells from etoposide-induced apoptosis ( Fig. 4d and Supplementary Fig. 4a ). We next determined whether BAX and BAK are activated in QKO cells on DNA damage. Indeed, both BAX and BAK homo-oligomers were detected in QKO cells on etoposide at a later time point (Fig. 4e) . Consequently, knockdown of either Bax or Bak partially inhibited whereas knockdown of both Bax and Bak near completely blocked etoposide-induced apoptosis in QKO cells ( Fig. 4f and Supplementary Fig. 4a ). Together, these data indicate that DNA damage can activate BAX-BAK in transformed
The low amplitude of cytochrome c efflux and caspase activation suggest that this mode of BAX and BAK activation is less efficient than that involving BID, BIM, PUMA and NOXA. Bid −/− Bim −/− Puma −/− Noxa −/− QKO (n = 3) mice at 8 to 10 weeks of age were cultured in the absence of cytokine, in the presence of etoposide, in the presence of dexamethasone, or after exposure to 2.5 Gy γ-irradiation. Cell death was quantified by annexin-V staining at the indicated times (mean ± s.d.). * * , P < 0.01; * * * , P < 0.001 (Student's t-test).
spontaneous apoptosis in QKO cells (Fig. 5b) . The inability of BH3s other than BID, BIM, PUMA and NOXA to kill QKO cells raises a possibility that an alternative, BH3-independent mechanism may be involved in the activation of BAX-BAK in QKO cells on DNA damage.
Although most BAX and BAK proteins do not interact with anti-apoptotic BCL-2s in viable cells 6, 7 , those complexed with anti-apoptotic BCL-2s probably have already exposed their BH3 domains that bind to the hydrophobic dimerization groove of Cell death was quantified by annexin-V staining at the indicated times (mean ± s.d., n = 3 independent experiments). * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 (Student's t-test).
anti-apoptotic BCL-2s (refs 3,7) . Foreseeably, if anti-apoptotic BCL-2s are downregulated by DNA damage in QKO MEFs, the 'BH3-exposed' monomers of BAX-BAK will probably be liberated to activate other native molecules of BAX-BAK, initiating 'autoactivation' . Indeed, BCL-2, BCL-X L and MCL-1 were decreased in QKO MEFs on etoposide treatment (Fig. 5c ). In contrast, no concurrent downregulation of anti-apoptotic BCL-2s was detected in QKO MEFs on ER stress (Fig. 5c) . Significantly, proteasome inhibition mitigated DNA damage-induced decrease of anti-apoptotic BCL-2s, and consequently protected QKO cells from etoposide-induced apoptosis (Fig. 5d,e) . Of note, etoposide-induced downregulation of BCL-2 and BCL-X L was also observed in wild-type MEFs but not in T cells ( Supplementary Fig. 5a,b) . Interestingly, ultraviolet but not ionizing radiation could induce downregulation of anti-apoptotic BCL-2s in Percentage of death QKO cells (Supplementary Fig. 5c ). Consequently, QKO cells were almost as resistant as Bax −/− Bak −/− cells to ionizing radiation but succumbed to ultraviolet ( Supplementary Fig. 5d and Fig. 3h) .
To further confirm that loss of anti-apoptotic BCL-2s can lead to autoactivation of BAX-BAK and apoptosis, short interfering RNA (siRNA)-mediated knockdown of anti-apoptotic BCL-2s was performed. Concurrent knockdown of Bcl-2, Bcl-x L and Mcl-1 induced significant apoptosis after 2 days in wild-type, TKO and QKO cells but not in Bax −/− Bak −/− cells in the absence of any death stimulus ( Fig. 5f and Supplementary Fig. 4a ). Interestingly, knockdown of both Bcl-x L and Mcl-1 was sufficient to induce spontaneous apoptosis. Of note, knockdown of Bcl-2, Bcl-x L or Mcl-1 did not sensitize QKO cells to overexpression of BAD, BMF, BIK or HRK ( Supplementary  Fig. 5e ). Given that the basal levels of activator BH3s are low in healthy cells and most of the activator BH3s are induced by intrinsic death signals, deficiency of activator BH3s seems to provide more protection against apoptosis triggered by intrinsic death signals than knockdown of anti-apoptotic BCL-2s. It is noteworthy that overexpression of NOXA induces more apoptosis than knockdown of Mcl-1 in MEFs (Fig. 5b,f) , supporting that NOXA does not simply induce apoptosis by inactivating MCL-1.
Liberation of the 'BH3-exposed' BAK monomers from anti-apoptotics initiates a feed-forward amplification loop for the activation of mitochondrial apoptosis (G138E/R139L/I140N) were untreated or treated with etoposide. Cell death was quantified by annexin-V staining at the indicated times (mean ± s.d., n = 3 independent experiments). The expression of BCL-X L was analysed by an anti-BCL-X L immunoblot. * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 (Student's t-test). Unprocessed original scans of blots are shown in Supplementary Fig. 7 .
(refs 23,37). Cleavage of BAK at the BH3 domain by trypsin generates a ∼15 kDa C-terminal fragment (p15) that is tethered to the mitochondria through the carboxy-terminal transmembrane anchor. Indeed, cleaved BAK p15 was detected in QKO cells on etoposide treatment (Fig. 5g) , suggesting that the 'BH3-exposed' BAK is liberated from the anti-apoptotic BCL-2s in QKO cells on DNA damage. Furthermore, BAK cleavage at the BH3 domain was observed in QKO cells on knockdown of both Bcl-x L and Mcl-1 (Fig. 5h) . Of note, only low levels of BAK p15 could be detected because the 'BH3-exposed' BAK probably binds to the hydrophobic groove of another BAK molecule immediately 23 . Limited proteolysis of BAK also revealed another feature of BAK activation, that is, exposure of the α1 helix or BH4 domain, leading to the generation of a 19 kDa mitochondrially targeted C-terminal fragment p19 (Fig. 5g,h ) These data suggest that liberation of the 'BH3-exposed' BAK from anti-apoptotic BCL-2s may induce a 'feed-forward' mechanism to activate other native molecules of BAX-BAK. Accordingly, even a small fraction of 'BH3-exposed' BAX-BAK monomers that are set free from the anti-apoptotic BCL-2s is sufficient to initiate the mitochondrial apoptotic program. Collectively, these data support a model in which BAX and BAK can undergo autoactivation on DNA damage through downregulation of anti-apoptotic BCL-2s in transformed 
BCL-X L is superior to BCL-2 and MCL-1 in preventing DNA damage-induced apoptosis
The loss-of-function studies of anti-apoptotic BCL-2s suggest that BCL-2 may be less important than BCL-X L and MCL-1 in gauging cellular survival (Fig. 5f ). This could be due to the fact that BCL-2 interacts only with BAX but not BAK (refs 37,38) . In QKO cells, co-immunoprecipitation assays demonstrated that BAX interacted with BCL-2, BCL-X L and MCL-1 whereas BAK interacted only with BCL-X L and MCL-1 but not BCL-2 (Fig. 6a) . The same interaction profiles were also observed in WT and TKO MEFs ( Supplementary  Fig. 5f ), which is consistent with previously published results 27, 38 . Notably, the same results were obtained using either CHAPS or NP-40 buffer except that more heterodimers were detected in the presence of NP-40 than CHAPS (Fig. 6a) . Consistent with the notion that most endogenous BAX-BAK does not interact with anti-apoptotic BCL-2s in viable cells 6, 7 , only a portion of BAX-BAK was co-precipitated with anti-apoptotic BCL-2s (Fig. 6a) .
We next investigated whether anti-apoptotic BCL-2s might exhibit differential activity against DNA damage in QKO cells. Indeed, overexpression of BCL-2 provided less protection to QKO cells against etoposide-induced apoptosis than BCL-X L (Fig. 6b) . Surprisingly, MCL-1 also provided less protection than BCL-X L even though both interact with BAX and BAK. The lesser protection conferred by MCL-1 is probably due to its labile nature, which is supported by the observation that overexpressed MCL-1 was rapidly degraded by etoposide within 12 h (Fig. 6b) . To further assess whether the differential activity of BCL-2 versus BCL-X L in regulating apoptosis is due to the inability of BCL-2 to inhibit BAK, we silenced Bax or Bak in QKO cells overexpressing BCL-2 or BCL-X L . Knockdown of Bak but not Bax further protected BCL-2-overexpressing QKO cells from etoposide-induced apoptosis (Fig. 6c) , suggesting that etoposide is capable of activating BAK in BCL-2-overexpressing cells. In contrast, knockdown of either Bax or Bak had no effect on BCL-X L in protecting QKO cells against etoposide (Fig. 6c) . Even in wild-type cells, overexpression of BCL-2 only delays whereas overexpression of BCL-X L completely blocks etoposide-induced apoptosis (Fig. 6d) . The delayed death kinetics observed in BCL-2-overexpressing cells further supports the lower efficiency of BAK autoactivation in triggering mitochondrial apoptosis. It is noteworthy that transformed Bax −/− Bak
−/−
MEFs still succumb to DNA damage-induced programmed necrotic death between 2-3 days that cannot be inhibited by overexpression of BCL-X L (ref. 39) . In aggregate, BCL-X L is superior to BCL-2 and MCL-1 in preventing DNA damage-induced apoptosis owing to its dual inhibition of BAX and BAK as well as higher protein stability.
Binding to BAX and BAK is required for BCL-X L to inhibit apoptosis in QKO cells
To further illustrate that BCL-X L inhibits etoposide-induced apoptosis in QKO cells through sequestering BAX-BAK but not BH3s, we employed reported, distinct BCL-X L mutants that differentially interact with BH3s or BAX-BAK (refs 9,40) . The BCL-X L mutant 1 (F131V/D133A) known to interact with BH3s but not BAX-BAK protected wild-type but not QKO cells from etoposide-induced apoptosis (Fig. 6e) . Conversely, the BCL-X L mutant 8 (G138E/R139L/I140N) known to interact with neither BH3s nor BAX-BAK failed to inhibit apoptosis in both wild-type and QKO cells (Fig. 6e) . Together, these data suggest that BCL-X L protects wild-type cells through sequestration of either activator BH3s or multidomain BAX-BAK. In the absence of activator BH3s, BCL-X L binds to BAX-BAK to inhibit apoptosis. In summary, our data support a model in which anti-apoptotic BCL-2s keep both activator BH3s and the 'BH3-exposed' BAX-BAK monomers in check in viable cells. In response to intrinsic death signals, BID, BIM, PUMA and NOXA are activated through transcriptional regulation and/or posttranslational modifications, triggering the homo-oligomerization of BAX-BAK to initiate apoptosis. In addition, etoposide and ultraviolet decrease anti-apoptotic BCL-2s in transformed MEFs, resulting in autoactivation of BAX-BAK even in the absence of BID, BIM, PUMA and NOXA (Supplementary Fig. 6 ).
DISCUSSION
Our results support an interconnected hierarchical model in which the BCL-2 family proteins regulate mitochondrial apoptosis (Fig. 7) . BID, BIM, PUMA and NOXA activate BAX-BAK directly to induce stepwise, bimodal activation of BAX-BAK. Activator BH3s convert inactive BAX-BAK monomers to 'BH3-exposed' BAX-BAK monomers, initiating the activation of BAX-BAK. Subsequently, activator BH3s prevent anti-apoptotic BCL-2s from sequestering 'BH3-exposed' monomers of BAX-BAK, leading to homo-oligomerization of BAX-BAK. The anti-apoptotic BCL-2s inhibit both modes of BAX-BAK activation. First, they sequester activator BH3s to prevent the initiation of BAX-BAK activation, providing front-line protection 6, 9 . Second, the anti-apoptotic BCL-2s can also sequester 'BH3-exposed' BAX-BAK monomers to prevent the homo-oligomerization of BAX-BAK, serving as a fail-safe mechanism or the second line of defence. The interaction between activator BH3s and anti-apoptotic BCL-2s confers mutual inhibition because it not only prevents activator BH3s from activating BAX-BAK but also refrains the anti-apoptotics from sequestering the 'BH3-exposed' BAX-BAK monomers. Conceivably, BID, BIM and PUMA can prevent BCL-2, BCL-X L and MCL-1 from sequestering BAX-BAK whereas NOXA can only inhibit MCL-1. This difference may contribute to the lower death-inducing activity of NOXA in comparison with BID, BIM and PUMA (Fig. 5b) . Consequently, Noxa deficiency confers resistance to apoptosis only in tissues or cell types that express sufficient NOXA for the activation of BAX-BAK. The remaining BH3s, including BAD, BMF, BIK and HRK, cannot activate BAX-BAK directly and seem to promote apoptosis by preventing BCL-2 and BCL-X L from sequestering activator BH3s. NOXA is unique among all BH3s in the sense that it can prevent MCL-1 from sequestering BID, BIM and PUMA owing to its high binding affinity to MCL-1. The observation that deficiency of BID, BIM, PUMA and NOXA abrogates apoptosis triggered by overexpression of BAD, BMF, BIK or HRK (DP5) supports the BH3 hierarchy entailing upstream 'inactivator' BH3s and downstream 'activator' BH3s (ref. 6) .
The interaction between activator BH3s and multidomain BAX-BAK has been debated for decades owing to low binding affinity 27 . Recent biophysical demonstrations of BID, BIM or PUMA bound to BAX or BAK have helped revolve this controversy [18] [19] [20] [21] [22] . It is now recognized that the binding of activator BH3s to BAX-BAK has to be transient and dynamic to induce stepwise, bimodal activation of BAX-BAK (refs 14,18,19,22,24,41) . The interaction between activator BH3s and BAX-BAK should be 'hit-and-run' because the same binding pocket of BAX-BAK is utilized for homo-oligomerization. Hence, the low binding affinity between activator BH3s and BAX-BAK renders a simple solution. In contrast, BH3s bind tightly to the antiapoptotic BCL-2s. By analogy, the anti-apoptotic BCL-2s function like 'decoy' death receptors that form inert stable complexes with BH3s.
As BID, BIM and PUMA also bind and inactivate all of the antiapoptotic BCL-2s, it was proposed that BAX and BAK can be autoactivated once they are released from the anti-apoptotic BCL-2s by BID, BIM and PUMA (indirect activation model) 27 . The identification of NOXA as an activator of BAX-BAK argues against the indirect activation model because NOXA exhibits high binding affinity only to MCL-1 (refs 6,11-13) . Nonetheless, unequivocal evidence of indirect activation of BAX-BAK has not been revealed until our generation of
We demonstrated that autoactivation of BAX-BAK can occur in transformed QKO cells when anti-apoptotic BCL-2s are simultaneously decreased on DNA damage. However, autoactivation of BAX-BAK seems less efficient in part owing to the fact that only a small fraction of BAX-BAK is readily bound to anti-apoptotic BCL-2s whereby BH3 exposure is required for BAX-BAK to interact with anti-apoptotic BCL-2s. Therefore, activator BH3s probably function as catalysts for BAX-BAK activation by inducing the BH3 exposure of BAX-BAK, and at the same time restrain anti-apoptotic BCL-2s. The presence of heterodimers between antiapoptotic BCL-2s and BAX-BAK in QKO cells suggests that exposure of the BH3 domain in BAX-BAK can be generated independently of activator BH3s. Potential mechanisms include heat, changes in intracellular pH, oxidative stress, protein misfolding, or post-translational modifications 42 . It is possible that these heterodimers have important non-apoptotic functions in the maintenance of cellular homeostasis.
Retrotranslocation of BAX from the mitochondria to the cytosol mediated by BCL-X L seems to offer a means to reduce the BAX and BCL-X L heterodimers 43 , which may not only gauge apoptosis but also fine-tune non-apoptotic activities.
Many studies have employed peptides derived from the BH3 domains of BH3s (refs 10-13,41,44) . In principal, most BH3 peptides mimic full-length proteins in inhibiting anti-apoptotic BCL-2s. However, not all of the BH3 peptides can recapitulate full-length proteins in activating BAX-BAK. For example, whereas full-length PUMA protein has potent cytochrome c-releasing activity 6 , conflicting results have been reported with regard to the PUMA BH3 peptide 12, 13, 21, 45, 46 . Here, we show that full-length NOXA protein is capable of permeabilizing wild-type mitochondria and liposomes in the presence of BAX. As for PUMA BH3 peptide, inconsistent results have been obtained from NOXA BH3 peptide. NOXA BH3 peptide was shown to bind to BAK and induce BAK-dependent liposome permeabilization in one report but not another 19, 47 . One plausible explanation is that different peptide preparations result in different alpha helicity. Alternatively, regions other than the BH3 domain may enhance the interaction between PUMA-NOXA and BAX-BAK directly or indirectly.
The identification of NOXA as a missing activator of BAX-BAK and the creation of Bid −/− Bim −/− Puma −/− Noxa −/− QKO cells provide an unprecedented opportunity to solve the puzzle of the BCL-2 family signalling network. Our studies comparing cells deficient for upstream apoptotic initiators (activator BH3s) with those deficient for downstream apoptotic effectors (BAX and BAK) have helped resolve previously elusive, even contradictory, observations concerning the BCL-2 family proteins. Targeting the BCL-2 family to promote apoptosis holds great promise for cancer therapy [48] [49] [50] [51] [52] [53] . With recent advances in the development of small-molecule inhibitors of antiapoptotic BCL-2s and establishment of a comprehensive functional roadmap of BCL-2 family proteins, this goal is within reach.
METHODS
Methods and any associated references are available in the online version of the paper. Plasmid construction, retrovirus production, siRNA and shRNA. The indicated Bcl-2 members were cloned into pSG5 (Stratagene) or pCDNA3 (Life Technologies) for in vitro transcription and translation reactions and the retroviral expression vector MSCV-IRES-GFP (pMIG) or MSCV-Puro (Clontech). BCL-X L mutants were described previously 40 . The NOXA mutants were generated by PCR-based site-directed mutagenesis. The BH3 mutant of NOXA contains L27E and L78E mutations. The K/R mutant of NOXA contains K5R, K29R, K33R, K53R, K56R, K72R, K84R, K90R and K97R mutations. All of the constructs were confirmed by DNA sequencing. The production of retroviruses was described previously 6 . The following siRNA oligonucleotides were purchased from Ambion Silencer Select oligonucleotides (Applied Biosystems): Bax, 5 -GGAUGAUUGCU GACGUGGAtt-3 ; Bak, 5 -AUAUCAUACUGCAUCAUUAtt-3 ; cytochrome c, 5 -UGAUCUUCGCUGGAAUUAAtt-3 ; Bcl-2, 5 -CAUUAUAAGCUGUCAC AGAtt-3 ; Bcl-x L , 5 -UCAGUUUAGUGAUGUCGAAtt-3 ; Mcl-1, 5 -CCAAGA AAGCUUCAUCGAAtt-3 ; and Hrk, 5 -GGAUGAGAGGUUUCUAUUUtt-3 and 5 -GGAGGAAGCUGGUUCCUGUtt-3 . The siRNA oligonucleotides against caspase-9 were purchased from Dharmacon: 5 -UGGAUGCUGUGUCAAGUUU-3 . The scramble siRNA oligonucleotides were purchased from Applied Biosystems (Part number 4390844) and Dharmacon (D-001206-13-20); siRNA oligonucleotides were reverse-transfected using Lipofectamine RNAiMAX (Life Technologies) to a final concentration of 10 nM. Retrovirus-mediated knockdown constructs were generated using pSuper-Retro-Puro or pSuperior-Retro-Puro according to the manufacturer's instructions (Oligoengine). The shRNA target sequence for Bad is 5 -GTCCTGGTGGGATCGAAAC-3 . The shRNA target sequence for Bmf is 5 -G TCCTGGTGGGATCGAAAC-3 . The shRNA target sequence for Bik is 5 -GATTC GAAGCCTCACCAAC-3 . The shRNA target sequence for Apaf-1 is 5 -GAACGG TGAAGGTGTGGAA-3 .
Cell culture, viability assay, caspase-3/7 activity assay and TUNEL assay.
Mouse embryonic fibroblasts (MEFs) were generated from E13.5 embryos and cultured in IMEM supplemented with 20% fetal bovine serum (Life Technologies). All of the MEFs used in the experiments were within the first 3 passages. Apoptosis was induced in primary MEFs by 1 µg ml −1 tunicamycin, 2 µM thapsigargin, or cultured in the absence of serum or glucose. To generate E1A/Rastransformed MEFs, primary MEFs were infected with retrovirus expressing E1A-IRES-Ras as described previously 55 , followed by selection under 2 µg ml −1 of puromycin. Pools of puromycin-resistant cells were used for cell death assays. SV40 transformation was described previously 9 . Apoptosis was induced in E1A/Ras-or SV40-transformed MEFs by 10 µg ml −1 etoposide, 1 µg ml −1 tunicamycin, 2 µM thapsigargin, ultraviolet-C irradiation (250 or 500 J m −2 ), 20 Gy γ-irradiation, or cultured in the absence of serum, glucose or glutamine. Cell death was quantified by annexin-V (BioVision) staining, followed by flow cytometric analyses. Flow cytometry was performed using either a FACSCalibur (BD Biosciences) or a LSRFortessa (BD Biosciences). Data were analysed using CellQuest Pro (BD Biosciences) or FACSDiva (BD Biosciences). P values for statistical analyses were obtained using Student's t-test. The activity of caspase-3/7 in cells was assessed using the Caspase-Glo 3/7 Assay System (Promega) according to the manufacturer's instructions.
CD4+ T cells were isolated using anti-CD4 conjugated magnetic beads (Miltenyi). CD4 + T cells purified from the spleens of wild-type (two female and one male) Bid −/− Bim −/− Puma −/− TKO (two female and one male), or Bid −/− Bim −/− Puma −/− Noxa −/− QKO (three female) mice at 8 to 10 weeks of age were cultured in the absence of cytokine, in the presence of etoposide, in the presence of dexamethasone, or after exposure to 2.5 Gy γ-irradiation. Cell death was quantified by annexin-V staining at the indicated times. Wild-type (two female and one male), Bid −/− Bim −/− Puma −/− TKO (one female and two male), or Bid −/− Bim −/− Puma −/− Noxa −/− QKO (two female and one male) mice at 8 to 10 weeks of age were irradiated with 5 Gy total body irradiation. Three days later, total numbers of splenocytes and CD4 + splenocytes were assessed. The percentage of survival was defined as the numbers of viable cells from irradiated mice divided by those from unirradiated ones with the same genotypes.
Apoptosis in the small intestinal crypts of wild-type (three female), Bid −/− Bim −/− Puma −/− TKO (one female and two male), Bid −/− Bim −/− Puma −/− Noxa −/− QKO (one female and one male), or conditional Bax and Bak DKO (one female and one male) mice at 8 to 17 weeks of age at 4 h after 18 Gy whole body irradiation was assessed by TUNEL assays. The immunohistochemical TUNEL assay was performed at the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center. Slides were manually deparaffinized in xylene, re-hydrated in series of alcohol dilutions (100%, 95% and 70%) and tap water, placed in Discovery XT autostainer (Ventana Medical Systems), treated with Proteinase K (20 µg ml −1 in PBS) for 12 min and then incubated with TdT-biotin-dUTP labelling mix (Roche) for 1 h. The detection was performed with the DAB detection kit (Ventana Medical Systems) according to the manufacturer's instruction. Slides were counterstained with haematoxylin and coverslipped with Permount (Fisher Scientific). TUNEL-positive cells were quantified in 300 small intestinal crypts in each mouse under light microscopy.
In vitro transcription and translation, cytochrome c release assay, protein crosslinking, and GST-pulldown assay. In vitro transcription and translation (IVTT) reactions were performed with TNT T7 Quick Coupled Transcription/Translation Reticulocyte Lysate or Wheat Germ Extract Systems (L1170 and L4140, Promega) according to the manufacturer's instructions. For the Wheat Germ Extract System, SG5-and pCDNA3-based constructs were linearized with XbaI and NdeI, respectively. All of the constructs generated full-length BCL-2 family proteins with expected molecular weights validated by autoradiography. Mitochondria purification and cytochrome c release assays were performed as described previously 6 . Quantification of cytochrome c release was performed using colorimetric ELISA assays (MCTC0, R&D Systems). To obtain the percentage of cytochrome c release, the amount of cytochrome c present in mitochondrial supernatant was divided by total cytochrome c present in both mitochondrial supernatant and pellet. Crosslinking of BAX or BAK was performed as described previously 6 . Briefly, 5 or 10 mM BMH (Pierce) in dimethylsulphoxide was added to mitochondria for 30 min at room temperature. Approximately 2 µg of GST, GST-BAK C (amino acids 1-183), or GST-BAX C (amino acids 1-171) proteins were immobilized on glutathione-agarose beads (Sigma), followed by incubation with IVTT [ The dilution for all of the primary antibodies for immunoblot analysis was 1/1,000. For co-immunoprecipitation, cells were lysed in 0.2% NP40 isotonic buffer (0.2% NP40, 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EGTA, 20 mM HEPES at pH 7.5) or 1% CHAPS buffer (1% CHAPS, 142.5 mM KCl, 2 mM CaCl 2 , 20 mM Tris-Cl, pH 7.4) supplemented with complete protease inhibitors (Roche). Cell lysates were immunoprecipitated with anti-HA antibody (12CA5) and analysed by 10% NuPAGE (Life Technologies) and immunoblots using the indicated antibodies. To assess BAK cleavage by limited trypsin proteolysis, cells (5 × 10 5 ) were resuspended in 100 µl of PBS containing 0.02% digitonin and 30 µg ml −1 trypsin on ice for 30 min. Following quenching of protease activity with 100 µg ml −1 soybean trypsin inhibitor (Sigma), samples were analysed by anti-BAK (G23) immunoblots. All of the immunoblots shown are representative images from at least 2 independent experiments.
Reverse transcription and quantitative PCR. Total RNA was extracted from cells using TRIZOL (Life Technologies) according to the manufacturer's instructions. Reverse transcription was performed with oligo-dT plus random decamer primers (Ambion) using Superscript II (Life Technologies). Quantitative PCR was performed with SYBR green master mix (Applied Biosystems) in duplicates using the indicated gene-specific primers. Quantitative PCR was performed on a ViiA 7 Real-Time PCR System (Applied Biosystems). Data were analysed as described previously by normalization against GAPDH or 18S rRNA (ref. 55). The primers for quantitative PCR are as follows: Noxa, 5 -CCAGATTGGGGACCTTAGTCTCC-3 and 5 -AGT TGAGCACACTCGTCCTTCAAG-3 ; Bmf, 5 -CTTGTGGGGTGACAGAGGAAC C-3 and 5 -GGTCTCGGTTCTGCTGGTGT-3 ; Bik, 5 -GAGAGACGTGGACCT CATGGAG-3 and 5 -TGAGGCTTCGAATCAAGCTCCTG-3 ; and Hrk, 5 -GTG CTCACAGGGCTTAGGAG-3 and 5 -GTACTGCTGCAAGGAGAGGAG-3 .
Liposomal release assay. Liposomes were prepared, and release assays were performed as previously described 32, 56 . Liposomal composition reflects a mixture of the following molar percentages of lipids (Avanti Polar Lipids): phosphatidylcholine, 48%; phosphatidylethanolamine, 28%; phosphatidylinositol, 10%; dioleoyl phosphatidylserine, 10%; and tetraoleoyl cardiolipin, 4%. Aliquots of mixed lipids (1 mg total) are stored in glass at −20 • C under nitrogen, and before use, resuspended in liposome assay buffer (10 mM HEPES, 200 mM KCl, and 1 mM MgCl 2 (pH 7)) containing 12.5 mM fluorescent dye ANTS (8-aminonaphthalene-1,3,6-trisulphonic acid, disodium salt) and 45 mM quencher DPX (p-xylene-bis-pyridinium bromide). The resulting slurry is vortexed for 10 min and freeze-thawed five times in liquid nitrogen and a 40 • C water bath, respectively. The solution is then passed through an Avanti Mini-Extruder Set (no. 610000) equipped with a 100 nm filter, followed by passage through a Sepharose column (GE Healthcare) to remove residual ANTS/DPX. The liposomes are brought up to a volume of 3 ml to produce a final liposome stock. For the liposomal release assay, recombinant BAX (400 nM) is combined with IVTT tBID, wild-type NOXA or BH3 mutant NOXA at the indicated protein/ligand ratios in a 96-well black flat-bottom plate (Costar) and then 10 µl of liposomes is added to a final volume of 100 µl in liposome assay buffer. Liposomal release is quantified on the basis of the increase in fluorescence that occurs when the ANTS fluorophore is separated from the DPX quencher on release from the liposomes into the supernatant. Isolated wild-type mitochondria were incubated with IVTT mouse NOXA generated using wheat germ extract (WGE) in the absence or presence of reticulocyte lysates (R) or IVTT mouse NOXA generated using reticulocyte lysates (R) in the absence or presence of wheat germ extract (WGE) at 30 o C for 30 min, after which the release of cytochrome c was quantified by ELISA assays (mean ± s.d., n = 3 independent experiments).
(b) Isolated wild-type mitochondria were incubated with IVTT mouse tBID generated using wheat germ extract (WGE) in the absence or presence of reticulocyte lysates (R) at 30 o C for 30 min, after which the release of cytochrome c was quantified by ELISA assays (mean ± s.d., n = 3 independent experiments). Supplementary Figure 7 Full scans of immunoblots. In some experiments, membranes were cut prior to probing each strip with a separate antibody.
